Matthieu Mahevas
Overview
Explore the profile of Matthieu Mahevas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
2535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larue M, Moulis G, Rueter M, Audia S, Terriou L, Viallard J, et al.
Blood Adv
. 2025 Jan;
PMID: 39874521
To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-word study cohort were performed. Participants were adults with primary...
2.
Cottu A, Guillet S, Viallard J, Riviere E, Cheze S, Gobert D, et al.
Blood
. 2024 Oct;
145(2):244-247.
PMID: 39476101
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained...
3.
Mahevas M, Bussel J
Br J Haematol
. 2024 Oct;
205(4):1267-1268.
PMID: 39415321
The choice between thrombopoietin receptor agonists (TPO-RAs) and anti-CD20 as the preferred second-line therapies for immune thrombocytopenia remains in the eye of the beholders. Each has major advantages and certain...
4.
Dubois S, Layese R, Limal N, Languille L, Kini-Matondo W, Mahevas M, et al.
Br J Haematol
. 2024 Oct;
205(6):2425-2431.
PMID: 39389921
Intravenous immunoglobulin (IVIg) is the gold standard treatment for severe cases of immune thrombocytopenia (ITP). However, its cost, limited duration of efficacy and market supply tension have led French guidelines...
5.
Manfroi B, Cuc B, Sokal A, Vandenberghe A, Temmam S, Attia M, et al.
Sci Transl Med
. 2024 Sep;
16(765):eadl1997.
PMID: 39292802
The development of the human immune system lasts for several years after birth. The impact of this maturation phase on the quality of adaptive immunity and the acquisition of immunological...
6.
Dejoux A, Zhu Q, Ganneau C, Goff O, Godon O, Lemaitre J, et al.
Sci Transl Med
. 2024 Sep;
16(764):eado4463.
PMID: 39259810
Neuromuscular blocking agents (NMBAs) relax skeletal muscles to facilitate surgeries and ease intubation but can lead to adverse reactions, including complications because of postoperative residual neuromuscular blockade (rNMB) and, in...
7.
Guillet S, Loustau V, Boutin E, Souchaud-Debouverie O, Chalumeau N, Pascal L, et al.
Am J Hematol
. 2024 Jul;
99(10):2032-2036.
PMID: 38980201
No abstract available.
8.
Cohen E, Lheure C, Ingen-Housz-Oro S, Hotz C, Bettuzzi T, Chasset F, et al.
Eur J Dermatol
. 2024 Mar;
33(6):680-685.
PMID: 38465550
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ...
9.
Sokal A, Bastard P, Casanova J, Weill J, Chappert P, Mahevas M
Med Sci (Paris)
. 2024 Feb;
40(1):99-101.
PMID: 38299911
No abstract available.
10.
Moulis G, Rueter M, Duvivier A, Mahevas M, Viallard J, Comont T, et al.
Br J Haematol
. 2024 Jan;
204(4):1476-1482.
PMID: 38267268
The aim of this study was to assess the prevalence and the burden of difficult-to-treat primary ITP (pITP), defined by the need for another ITP treatment after romiplostim and eltrombopag....